IL273479B2 - Pharmaceutical compositions with enhanced permeation - Google Patents

Pharmaceutical compositions with enhanced permeation

Info

Publication number
IL273479B2
IL273479B2 IL273479A IL27347920A IL273479B2 IL 273479 B2 IL273479 B2 IL 273479B2 IL 273479 A IL273479 A IL 273479A IL 27347920 A IL27347920 A IL 27347920A IL 273479 B2 IL273479 B2 IL 273479B2
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
polymeric matrix
composition according
less
film
Prior art date
Application number
IL273479A
Other languages
English (en)
Hebrew (he)
Other versions
IL273479B1 (en
IL273479A (en
Original Assignee
Aquestive Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/724,234 external-priority patent/US11273131B2/en
Application filed by Aquestive Therapeutics Inc filed Critical Aquestive Therapeutics Inc
Publication of IL273479A publication Critical patent/IL273479A/en
Publication of IL273479B1 publication Critical patent/IL273479B1/en
Publication of IL273479B2 publication Critical patent/IL273479B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IL273479A 2017-09-27 2018-09-27 Pharmaceutical compositions with enhanced permeation IL273479B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201715717856A 2017-09-27 2017-09-27
US15/724,234 US11273131B2 (en) 2016-05-05 2017-10-03 Pharmaceutical compositions with enhanced permeation
US201862735822P 2018-09-24 2018-09-24
PCT/US2018/053026 WO2019067667A1 (en) 2017-09-27 2018-09-27 PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION

Publications (3)

Publication Number Publication Date
IL273479A IL273479A (en) 2020-05-31
IL273479B1 IL273479B1 (en) 2025-07-01
IL273479B2 true IL273479B2 (en) 2025-11-01

Family

ID=63858167

Family Applications (2)

Application Number Title Priority Date Filing Date
IL273479A IL273479B2 (en) 2017-09-27 2018-09-27 Pharmaceutical compositions with enhanced permeation
IL321263A IL321263A (en) 2017-09-27 2018-09-27 Pharmaceutical preparations with improved penetration

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL321263A IL321263A (en) 2017-09-27 2018-09-27 Pharmaceutical preparations with improved penetration

Country Status (8)

Country Link
EP (1) EP3687509A1 (https=)
JP (2) JP7431724B2 (https=)
KR (2) KR102845228B1 (https=)
CN (1) CN111132670A (https=)
BR (1) BR112020005967A2 (https=)
CA (1) CA3076815A1 (https=)
IL (2) IL273479B2 (https=)
WO (1) WO2019067667A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
BR112022008294A2 (pt) * 2019-11-01 2022-07-26 Aquestive Therapeutics Inc Composições de profármaco e métodos de tratamento
EP4072516A1 (en) 2019-12-09 2022-10-19 Nicoventures Trading Limited Oral product comprising a cannabinoid
DE102020122557A1 (de) * 2020-08-28 2022-03-03 Lts Lohmann Therapie-Systeme Ag Mucosa-Perforierung
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
EP4422607A4 (en) 2021-10-25 2025-09-03 Aquestive Therapeutics Inc ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT
CN114894675B (zh) * 2022-05-06 2024-04-19 江苏省农业科学院 一种农药助剂在植物叶片表面渗透行为的比较方法
EP4302750A1 (en) * 2022-07-07 2024-01-10 LTS Lohmann Therapie-Systeme AG Oral thin films comprising adrenaline
KR102949370B1 (ko) * 2023-12-29 2026-04-06 인하대학교 산학협력단 실시간 피부 투과도 측정 장치

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042271A1 (en) * 1999-11-19 2005-02-24 Xel Herbaceuticals, Inc . Transdermal delivery system for alkaloids of aconitum species
US20050266085A1 (en) * 2004-05-28 2005-12-01 Warner Kevin S Gelled emulsion and microemulsion formulations for dermal drug delivery
US8840935B2 (en) * 2006-05-01 2014-09-23 Biota Ltd. Orally administrable films and preparation thereof
US20140316333A1 (en) * 2011-10-28 2014-10-23 Sung-Yun Kwon Dissolving solid solution perforator patch for migraine treatment

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2165802A1 (en) * 1993-09-29 1995-04-06 Eun Soo Lee Monoglyceride/lactate ester permeation enhancer for oxybutynin
ATE355854T1 (de) * 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
JP2004043450A (ja) * 2002-05-16 2004-02-12 Kyukyu Yakuhin Kogyo Kk 速溶性フィルム状製剤
JP2004131495A (ja) * 2002-09-17 2004-04-30 Nippon Boehringer Ingelheim Co Ltd 非ステロイド系抗炎症剤の局所送達用医薬組成物
US20040127531A1 (en) * 2002-11-21 2004-07-01 Lu Guang Wei Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor
KR101159828B1 (ko) * 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
BR0302017B1 (pt) * 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
JP2006527764A (ja) * 2003-06-17 2006-12-07 エスケー コーポレイション ジアゼパムを含有する経鼻マイクロエマルジョン
US9125836B2 (en) * 2007-06-07 2015-09-08 Sato Pharmaceutical Co., Ltd. Film preparation with rapidly dissolving property and flexibility
JP5435853B2 (ja) * 2007-09-28 2014-03-05 興和株式会社 塩酸フェニレフリン含有速溶性フィルム製剤及びその製造方法
SG11201502425WA (en) * 2012-10-11 2015-05-28 Ix Biopharma Ltd Solid dosage form
EP3427732A1 (en) * 2013-07-31 2019-01-16 Intelgenx Corporation Instantly wettable oral film dosage form without surfactant or polyalcohol
EP3331496B1 (en) * 2015-08-05 2021-01-27 The University of Rochester Antimicrobial compositions comprising mupirocin and neomycin
WO2017192923A1 (en) * 2016-05-05 2017-11-09 Monosol Rx, Llc Pharmaceutical compositions with enhanced permeation
KR20230137362A (ko) * 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
CN105902524A (zh) * 2016-06-30 2016-08-31 合肥华方医药科技有限公司 一种酒石酸唑吡坦舌下膜及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042271A1 (en) * 1999-11-19 2005-02-24 Xel Herbaceuticals, Inc . Transdermal delivery system for alkaloids of aconitum species
US20050266085A1 (en) * 2004-05-28 2005-12-01 Warner Kevin S Gelled emulsion and microemulsion formulations for dermal drug delivery
US8840935B2 (en) * 2006-05-01 2014-09-23 Biota Ltd. Orally administrable films and preparation thereof
US20140316333A1 (en) * 2011-10-28 2014-10-23 Sung-Yun Kwon Dissolving solid solution perforator patch for migraine treatment

Also Published As

Publication number Publication date
JP2020535176A (ja) 2020-12-03
JP2024012484A (ja) 2024-01-30
KR20250126144A (ko) 2025-08-22
BR112020005967A2 (pt) 2020-10-06
CA3076815A1 (en) 2019-04-04
JP7431724B2 (ja) 2024-02-15
KR102845228B1 (ko) 2025-08-14
IL321263A (en) 2025-08-01
IL273479B1 (en) 2025-07-01
CN111132670A (zh) 2020-05-08
IL273479A (en) 2020-05-31
EP3687509A1 (en) 2020-08-05
KR20200060457A (ko) 2020-05-29
WO2019067667A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
US12023309B2 (en) Enhanced delivery epinephrine compositions
US20170290776A1 (en) Pharmaceutical compositions with enhanced permeation
KR102845228B1 (ko) 강화된 투과를 가지는 약물학적 조성물
US12433850B2 (en) Enhanced delivery epinephrine and prodrug compositions
JP2023159150A (ja) 増強された送達のエピネフリン及びプロドラッグ組成物
US11273131B2 (en) Pharmaceutical compositions with enhanced permeation
US20190022022A1 (en) Pharmaceutical compositions with enhanced permeation
US12427121B2 (en) Enhanced delivery epinephrine compositions
US20250108017A1 (en) Enhanced delivery epinephrine and prodrug compositions
US20180125977A1 (en) Enhanced delivery epinephrine compositions
US20240016734A1 (en) Enhanced delivery epinephrine and prodrug compositions
US20240148673A1 (en) Enhanced delivery epinephrine and prodrug compositions
WO2026024790A1 (en) Methods of administering enhanced delivery epinephrine and prodrug compositions